mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Structure == Draculin is a single-chain protein composed of 708 amino acids, weighing about 83 kDa with a pI of 4.1-4.2. When reduced, the gel electrophoresis data indicates a slightly higher molecular mass suggesting intra-chain disulphide bonds. There are two different structural forms of Draculin. However, the two forms do not significantly differ from the other. Both structures are able to and do bind to coagulation factors IXa and Xa. The main difference is evident in inhibition activity. One structural form will inhibit factor IXa and the other Xa. The inhibitory activity of one factor is not affected by the presence of the other. FXa-Draculin complex is a two-step mechanism that, through experimental conditions, is irreversible.
In 2007, Pritzker and his wife donated $5 million to the University of South Dakota to build the Theodore R. and Karen K. Muenster University Center in honor of his wife's parents. In 2011, Milton Academy dedicated the Pritzker Science Center for which Pritzker provided the lead gift. Pritzker is a trustee and serves on the investment committee of Northwestern University. He is a member of the Board of Governors of Northwestern University School of Law. He is a member of the Economic Club of Chicago and the Commercial Club of Chicago. He joined the Duke University Board of Trustees in 2017; his term expires in 2023. On October 22, 2015, Northwestern University School of Law announced that Pritzker and his wife, M. K. Pritzker, had made a $100-million gift to the school in honor of Pritzker's great-grandfather, Nicholas J. Pritzker. The 156-year-old school was renamed the Northwestern Pritzker School of Law. Pritzker received the Spirit of Erikson Institute Award for his creation of the Children's Initiative. Pritzker organized the White House Summit on Early Childhood Education for President Barack Obama in 2014 and helped expand school breakfast programs in Illinois to over 230,000 kids in low income school districts. The Better Government Association, an Illinois watchdog, has criticized Pritzker's charitable giving practices, saying he funneled the funds he gave to charity from offshore tax havens. "The result is that Pritzker's philanthropy, and any accolades that go with it, have been bankrolled with what is essentially found money.
Medical treatment of gynecomastia that has persisted beyond two years is often ineffective. Gynecomastia is different from "pseudogynecomastia", which is commonly present in men with obesity. Medications such as aromatase inhibitors are effective, even in rare cases of gynecomastia from disorders such as aromatase excess syndrome or Peutz–Jeghers syndrome, but surgical removal of the excess tissue can be needed to correct the condition. In 2019, 24,123 male patients underwent the procedure in the United States, accounting for a 19% increase since 2000.
=== Role in periodontal tissues === Elaunin fibers in the periodontal ligament (PDL) have connective tissue that anchors each tooth to the surrounding bone and helps cushion the forces we generate while chewing. In studies on rat molars, researchers found that elaunin fibers appear alongside oxytalan and mature elastic fibers. It forms a flexible network that allows the PDL to stretch during function and then return to its original shape (Sawada et al., 2006).
Sources: en.wikipedia.org
=== Alloys === Plutonium can form alloys and intermediate compounds with most other metals. Exceptions include lithium, sodium, potassium, rubidium and caesium of the alkali metals; and magnesium, calcium, strontium, and barium of the alkaline earth metals; and europium and ytterbium of the rare earth metals. Partial exceptions include the refractory metals chromium, molybdenum, niobium, tantalum, and tungsten, which are soluble in liquid plutonium, but insoluble or only slightly soluble in solid plutonium. Gallium, aluminium, americium, scandium and cerium can stabilize δ-phase plutonium for room temperature. Silicon, indium, zinc and zirconium allow formation of metastable δ state when rapidly cooled. High amounts of hafnium, holmium and thallium also allows some retention of the δ phase at room temperature. Neptunium is the only element that can stabilize the α phase at higher temperatures. Plutonium alloys can be produced by adding a metal to molten plutonium. If the alloying metal is reductive enough, plutonium can be added in the form of oxides or halides. The δ phase plutonium–gallium alloy (PGA) and plutonium–aluminium alloy are produced by adding Pu(III) fluoride to molten gallium or aluminium, which has the advantage of avoiding dealing directly with the highly reactive plutonium metal.
This was part of a larger transition in world views (the rise of the mechanical philosophy) that continued into the 17th century, as the traditional metaphor of nature as organism was replaced by the nature as machine metaphor.
An airport road was paved over the Jewish cemetery in Damascus, and Jewish schools were closed and handed over to Muslims. The Jewish Quarter of Damascus was under constant surveillance by the secret police, who were present at synagogue services, weddings, bar mitzvahs, and other Jewish gatherings. The secret police closely monitored contact between Syrian Jews and foreigners and kept a file on every member of the Jewish community. Jews also had their phones tapped and their mail read by the secret police. After Israel's victory in the 1967 Six-Day War, restrictions were further tightened, and 57 Jews in Qamishli may have been killed in a pogrom. The communities of Damascus, Aleppo, and Qamishli were under house arrest for eight months following the war. Many Jewish workers were laid off following the Six-Day War. After purging rival Baathist factions through a coup in 1970, Hafez al-Assad established total dominance over the Ba'ath party and established a dictatorship centered around his personality cult. Structure of Assad's police state revolved around the Ba'ath party organization, Syrian military establishment packed with Ba'athist elites and Assad family's Alawite loyalists. Hafez ruled Syria for three decades, deploying repressive measures ranging from censorship to violent methods of state terror such as mass murders, deportations and practices such as torture, which were unleashed collectively upon the civilian population.
=== Anatomical location === Necrotizing fasciitis can occur at any part of the body, but it is more commonly seen at the extremities, perineum, and genitals. A small fraction of cases arise in the head/neck, chest, and abdomen.
The quality of a vacuum is indicated by the amount of matter remaining in the system, so that a high quality vacuum is one with very little matter left in it. Vacuum is primarily measured by its absolute pressure, but a complete characterization requires further parameters, such as temperature and chemical composition. One of the most important parameters is the mean free path (MFP) of residual gases, which indicates the average distance that molecules will travel between collisions with each other. As the gas density decreases, the MFP increases, and when the MFP is longer than the chamber, pump, spacecraft, or other objects present, the continuum assumptions of fluid mechanics do not apply. This vacuum state is called high vacuum, and the study of fluid flows in this regime is called particle gas dynamics. The MFP of air at atmospheric pressure is very short, 70 nm, but at 100 mPa (≈10−3 Torr) the MFP of room temperature air is roughly 100 mm, which is on the order of everyday objects such as vacuum tubes. The Crookes radiometer turns when the MFP is larger than the size of the vanes. Vacuum quality is subdivided into ranges according to the technology required to achieve it or measure it. These ranges were defined in ISO 3529-1:2019 as shown in the following table (100 Pa corresponds to 0.75 Torr; Torr is a non-SI unit):
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.